ABSTRACT
Purpose@#To determine whether travoprost 0.003% has a similar intraocular pressure (IOP) reduction effect to that of travoprost 0.004% while reducing side effects. @*Methods@#This was a prospective study from January 2018 to December 2018 that included 102 patients diagnosed with open angle glaucoma who switched from travoprost 0.004% to travoprost 0.003%. We investigated the changes in IOP, conjunctival hyperemia, corneal erosion, and eyelid pigmentation before and at 3 months after switching to travoprost 0.003%. Additionally, a questionnaire survey of these patients was conducted to determine possible side effects, including hyperemia, stinging, pruritus, irritation, blurred vision, dryness, and foreign body sensation. @*Results@#IOP readings before and after switching to travoprost 0.003% were 12.95 ± 4.25 and 12.94 ± 3.89 mmHg, respectively, showing no significant change (p = 0.974). No changes were observed in corneal erosion or eyelid pigmentation; however, conjunctival hyperemia was reduced significantly from 1.60 ± 0.88 to 1.36 ± 0.84 (p = 0.001). No significant changes in hyperemia, stinging, pruritus, irritation, or foreign body sensation were reported; however, a significant improvement was noted for blurred vision and dryness (p = 0.008, p = 0.007, respectively). @*Conclusions@#We were able to show the effectiveness and safety of travoprost 0.003% as being as effective as travoprost 0.004% in reducing IOP and injections while improving blurred vision and dryness.
ABSTRACT
Purpose@#To determine whether travoprost 0.003% has a similar intraocular pressure (IOP) reduction effect to that of travoprost 0.004% while reducing side effects. @*Methods@#This was a prospective study from January 2018 to December 2018 that included 102 patients diagnosed with open angle glaucoma who switched from travoprost 0.004% to travoprost 0.003%. We investigated the changes in IOP, conjunctival hyperemia, corneal erosion, and eyelid pigmentation before and at 3 months after switching to travoprost 0.003%. Additionally, a questionnaire survey of these patients was conducted to determine possible side effects, including hyperemia, stinging, pruritus, irritation, blurred vision, dryness, and foreign body sensation. @*Results@#IOP readings before and after switching to travoprost 0.003% were 12.95 ± 4.25 and 12.94 ± 3.89 mmHg, respectively, showing no significant change (p = 0.974). No changes were observed in corneal erosion or eyelid pigmentation; however, conjunctival hyperemia was reduced significantly from 1.60 ± 0.88 to 1.36 ± 0.84 (p = 0.001). No significant changes in hyperemia, stinging, pruritus, irritation, or foreign body sensation were reported; however, a significant improvement was noted for blurred vision and dryness (p = 0.008, p = 0.007, respectively). @*Conclusions@#We were able to show the effectiveness and safety of travoprost 0.003% as being as effective as travoprost 0.004% in reducing IOP and injections while improving blurred vision and dryness.
ABSTRACT
Purpose@#We used optical coherence tomography angiography (OCTA) to evaluate changes in the vessel densities of macular capillary plexuses after cataract surgery. @*Methods@#We performed a retrospective chart review of 24 eyes of 24 cataract patients who underwent phacoemulsification cataract surgery from July 2018 to June 2019. The changes in vessel density (VD) in the macular superficial capillary plexus (SCP), the deep capillary plexus (DCP), inside the disc, and in the peripapillary area and foveal avascular zone (FAZ), were analyzed on OCTA images obtained preoperatively and at 1 week, and 1, 3, and 6 months, postoperatively. @*Results@#The VDs of the foveal SCP and DCP increased significantly from 15.42 ± 6.61 and 28.43 ± 7.62% preoperatively to 17.20 ± 6.21 and 30.52 ± 7.06% at 6 months postoperatively (p < 0.001, p = 0.001). The VDs of the parafoveal SCP and DCP increased significantly from 47.28 ± 5.76 and 53.06 ± 3.89% preoperatively to 50.34 ± 5.00 and 53.90 ± 4.20% at 6 months postoperatively (p = 0.002, p = 0.014). The VDs of the perifoveal SCP and DCP increased significantly from 45.20 ± 5.01 and 46.62 ± 5.89% preoperatively to 48.52 ± 4.32 and 50.96 ± 5.57% at 6 months postoperatively (p < 0.001, p = 0.002). The VDs of the area inside the disc, and of the peripapillary area and FAZ, did not change significantly (p = 0.068, 0.332, and 0.206, respectively). @*Conclusions@#After cataract surgery, the VDs of the SCP and DCP increased significantly at 1 week, and 1, 3, and 6 months, postoperatively.
ABSTRACT
Purpose@#To establish a corneal-fibroblast senescence model induced by ultraviolet B (UVB) exposure and to investigate the anti-senescence effect of angiogenin (ANG). @*Methods@#Fibroblasts were exposed to UVB (1 mJ/cm 2 ) and then cultured with ANG-containing solution for 24 hours. The 24-hour culture procedure was repeated for three days after UVB irradiation. Cell viability was evaluated using the 3-[4, 5–dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT) assay. The degree of senescence was assessed using the ratio of senescence-associated (SA)-β-gal-stained cells to total cells. The expression of age-related factors and degree of DNA damage were assessed via Western blot. Samples were divided into a non-UVB group, a UVB group without ANG treatment, and a UVB group with ANG treatment after irradiation (UVB + ANG). @*Results@#Cell viability in the UVB + ANG group was 11% higher than that in the UVB group (p < 0.05). The UVB + ANG group exhibited a 10% lower degree of SA-β-gal staining compared with the UVB group (p < 0.05). Western blot analysis showed that there was reduced expression of p53, p21, p16, and RB in the UVB + ANG group compared with the UVB group. The expression of phosphorylated histone (Y-H2AX) and p38 in the UVB + ANG group was less than that in the UVB group. @*Conclusions@#Senescence in corneal fibroblasts is induced by UVB, and ANG may exert an anti-aging effect by regulating the cell cycle through p53, p21, p16, and RB and reducing DNA damage.
ABSTRACT
Purpose@#We used optical coherence tomography angiography (OCTA) to evaluate changes in the vessel densities of macular capillary plexuses after cataract surgery. @*Methods@#We performed a retrospective chart review of 24 eyes of 24 cataract patients who underwent phacoemulsification cataract surgery from July 2018 to June 2019. The changes in vessel density (VD) in the macular superficial capillary plexus (SCP), the deep capillary plexus (DCP), inside the disc, and in the peripapillary area and foveal avascular zone (FAZ), were analyzed on OCTA images obtained preoperatively and at 1 week, and 1, 3, and 6 months, postoperatively. @*Results@#The VDs of the foveal SCP and DCP increased significantly from 15.42 ± 6.61 and 28.43 ± 7.62% preoperatively to 17.20 ± 6.21 and 30.52 ± 7.06% at 6 months postoperatively (p < 0.001, p = 0.001). The VDs of the parafoveal SCP and DCP increased significantly from 47.28 ± 5.76 and 53.06 ± 3.89% preoperatively to 50.34 ± 5.00 and 53.90 ± 4.20% at 6 months postoperatively (p = 0.002, p = 0.014). The VDs of the perifoveal SCP and DCP increased significantly from 45.20 ± 5.01 and 46.62 ± 5.89% preoperatively to 48.52 ± 4.32 and 50.96 ± 5.57% at 6 months postoperatively (p < 0.001, p = 0.002). The VDs of the area inside the disc, and of the peripapillary area and FAZ, did not change significantly (p = 0.068, 0.332, and 0.206, respectively). @*Conclusions@#After cataract surgery, the VDs of the SCP and DCP increased significantly at 1 week, and 1, 3, and 6 months, postoperatively.